- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.09. | Estrella Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.08. | Estrella Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | Estrella Immunopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| ESTRELLA IMMUNOPHARMA Aktie jetzt für 0€ handeln | |||||
| 29.07. | Estrella Immunopharma aktiviert zweiten Standort für EB103-Lymphomstudie | 1 | Investing.com Deutsch | ||
| 30.06. | Estrella Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | Estrella Immunopharma, Inc. - 10-K/A, Annual Report | - | SEC Filings |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CELLECTAR BIOSCIENCES | 2,390 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,272 | +2,26 % | Onco-Innovations Ltd: Onco-Innovations issues 860,168 shares for debt | ||
| CEL-SCI | 1,290 | 0,00 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,767 | -0,75 % | Moleculin Biotech droht Delisting von der NASDAQ nach Verstoß gegen Mindestkursanforderung | ||
| PDS BIOTECHNOLOGY | 0,736 | +4,84 % | PDS Biotechnology Corporation: PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors | Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation... ► Artikel lesen | |
| GEOVAX LABS | 0,368 | +3,14 % | EQS-News: GeoVax, Inc.: GeoVax Confirms Bundibugyo Ebola Vaccine Construct | EQS-News: GeoVax, Inc.
/ Key word(s): Science
GeoVax Confirms Bundibugyo Ebola Vaccine Construct 16.09.2026 / 14:37 CET/CEST
The issuer is solely responsible for the content... ► Artikel lesen | |
| COCRYSTAL | 0,965 | 0,00 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| LISATA THERAPEUTICS | 1,570 | +7,53 % | XFRA 8NE: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLISATA THERAP.INC.DL-... ► Artikel lesen | |
| DECOY THERAPEUTICS | 2,780 | 0,00 % | Aktionäre von Decoy Therapeutics stimmen Ausgabe von Optionsscheinen und Aktienreduzierung zu | ||
| JASPER THERAPEUTICS | 0,618 | 0,00 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Key Regulatory and Clinical Appointments | Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development REDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE... ► Artikel lesen | |
| CHEMOMAB THERAPEUTICS | 2,590 | -0,77 % | Chemomab Therapeutics Ltd.: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update | Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected by year-end RA is a $24 billion... ► Artikel lesen | |
| VISTAGEN THERAPEUTICS | 0,244 | +1,67 % | Vistagen Therapeutics, Inc.: Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update | Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA engagement planned... ► Artikel lesen | |
| IN8BIO | 0,905 | -1,63 % | IN8bio, Inc: IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development | Renowned ?d T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio's leadership and domain expertise as they... ► Artikel lesen | |
| METAVIA | 1,730 | 0,00 % | MetaVia Inc.: MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction | Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support... ► Artikel lesen | |
| EVAXION | 3,330 | +1,83 % | Evaxion applies its AI-Immunology platform in autoimmune diseases | Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology to target underlying pathologiesThe unique capabilities... ► Artikel lesen |
ESTRELLA IMMUNOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,78 % bei einem Aktienkurs von 0,520 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ESTRELLA IMMUNOPHARMA INC finden Sie auf Wallstreet Online.